Exane Derivatives Argenx Se Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Argenx Se stock. As of the latest transaction made, Exane Derivatives holds 6 shares of ARGX stock, worth $3,548. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6
Previous 111
94.59%
Holding current value
$3,548
Previous $34,000
94.12%
% of portfolio
0.0%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding ARGX
# of Institutions
384Shares Held
31.6MCall Options Held
338KPut Options Held
449K-
Price T Rowe Associates Inc Baltimore, MD5.6MShares$3.31 Billion0.29% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.51MShares$2.08 Billion2.39% of portfolio
-
Janus Henderson Group PLC London, X02.47MShares$1.46 Billion0.58% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD1.92MShares$1.14 Billion0.52% of portfolio
-
Capital World Investors Los Angeles, CA1.51MShares$894 Million0.11% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $32.7B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...